model,flat_path,key_cat,val_cat,ref_val,pred_val,val_match,sim,score_status,piece,norm_path,from_pred,in_ref,in_pred,type_mismatch,is_enum,sim_failed
Claude-4.5-Sonnet,protocolSection.identificationModule.nctId,TP,TP,NCT03388164,NCT03388164,True,1.0,exact,NCTId,protocolSection.identificationModule.nctId,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.briefTitle,TP,TP,Adherence to Antidepressant Treatment in Subjects With Depression,Methylphenidate augmentation to increase adherence to antidepressant medication in individuals with moderate to severe depression,True,0.86,success,BriefTitle,protocolSection.identificationModule.briefTitle,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.officialTitle,TP,TP,Adherence to Antidepressant Treatment in Subjects With Depression,A Phase 2a randomized placebo-controlled clinical trial to determine whether methylphenidate augmentation results in higher rates of medication adherence relative to placebo in individuals with moderate to severe depression,True,0.86,success,OfficialTitle,protocolSection.identificationModule.officialTitle,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.descriptionModule.briefSummary,TP,TP,"This study aims to determine whether a combination a first-line antidepressant plus ""RT2CK17"" in a capsule relative to a first-line antidepressant plus placebo in a capsule results in higher rates of medication adherence in individuals with moderate to severe depression. In this double-blind randomized placebo controlled trial, 100 individuals with a Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR) scale score ≥ 14 will be enrolled to participate in an 8 week treatment study. Participants will be randomized with a 1-1 ratio to receive 5 milligrams (mg) ""RT2CK17"" + 10 mg escitalopram or placebo + 10 mg escitalopram to be taken orally once per day. Participants will undergo a 3 hour baseline evaluation visit at week 0, two 30-minute office visits (week 2 and 4), one 60-minute office visit (week 8) and three 5-minute phone calls (weeks 1, 3, and 6) during which clinical assessments and measures will be obtained. The trial is designed with two stages: 20 participants in Stage 1 will be used to estimate the adherence effect size; Stage 2 is designed with an interim analysis to test our hypotheses.",This Phase 2a randomized placebo-controlled clinical trial investigated whether combining methylphenidate (MPH) with escitalopram would improve medication adherence in individuals with moderate to severe depression. The hypothesis was that pairing an acute positive reinforcing dopaminergic/noradrenergic effect (MPH) with a standard antidepressant would increase rates of adherence to medication treatment by facilitating habit formation. The study aimed to determine whether MPH + escitalopram resulted in higher rates of medication adherence compared to placebo + escitalopram over an 8-week treatment period.,True,0.95,success,BriefSummary,protocolSection.descriptionModule.briefSummary,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.descriptionModule.detailedDescription,EV,EV,,"Adherence to antidepressant treatment is a critical challenge in mental health care, with only one out of five patients complying with treatment for over 4 months. Non-adherence leads to adverse consequences including increased relapse, recurrence, and significant healthcare costs. This study was based on the premise that forming new treatment-related habits requires a transition from reward-related to habit-based behavioral strategies. Depressed individuals face specific barriers to habit formation including reduced hedonic processing mediated by impaired dopaminergic function and compromised functioning of neural circuits involved in habit formation (hippocampus to basal ganglia transition).

The trial utilized a two-stage Bayesian design with Stage 1 enrolling 20 participants (1:1 randomization) to receive either (1) 5 mg MPH + 10 mg escitalopram or (2) placebo + 10 mg escitalopram, encapsulated together, with possible dose escalation to 20 mg escitalopram at week 4. Participants were followed for 8 weeks with in-person visits at weeks 0, 2, 4, and 8, and phone follow-ups at weeks 1, 3, and 6.

The primary endpoint was percent adherence measured by pill count. The secondary endpoint was percent of doses taken on schedule (within ±6 hours of usual time) measured by Medication Electronic Monitoring System (MEMS). Exploratory endpoints included the Beliefs About Medicines Questionnaire (BMQ), remission rates (QIDS-SR ≤5), and response rates (50% reduction in QIDS-SR scores).

Methylphenidate was selected based on its mechanism as a monoaminergic reuptake inhibitor that blocks dopamine reuptake transporters and increases dopamine and norepinephrine availability. Unlike amphetamines or cocaine, MPH has relatively weak reinforcing properties and lower abuse liability. It has been used successfully in treating ADHD and has shown benefits in cognitive symptoms following brain injury.

The Bayesian statistical approach allowed for continuous evaluation of treatment effects using informative and weakly informative priors, with planned interim analysis to determine study continuation. Linear mixed-effects models evaluated treatment effects on adherence outcomes controlling for visit effects and treatment-by-visit interactions. Stage 2 (planned 80 additional participants) was not completed as Stage 1 results showed effects opposite to the hypothesis with low posterior probabilities (<25%) that MPH was superior to placebo.",,,,DetailedDescription,protocolSection.descriptionModule.detailedDescription,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.conditionsModule.conditions,TP,FP,['Depression'],"['Major Depressive Disorder', 'Depression, Moderate', 'Depression, Severe']",False,0.0,disjoint,Condition,protocolSection.conditionsModule.conditions,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.conditionsModule.keywords,EV,EV,,"['Medication Adherence', 'Treatment Adherence', 'Antidepressant Agents', 'Escitalopram', 'Methylphenidate', 'Dopamine Uptake Inhibitors', 'Habit Formation', 'Reinforcement, Psychology', 'Depression', 'Medication Compliance', 'Electronic Medication Monitoring', 'Beliefs About Medicines']",,,,Keyword,protocolSection.conditionsModule.keywords,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.studyType,TP,TP,INTERVENTIONAL,INTERVENTIONAL,True,1.0,exact,StudyType,protocolSection.designModule.studyType,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.patientRegistry,EV,EV,,False,,,,PatientRegistry,protocolSection.designModule.patientRegistry,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.phases,TP,TP,['PHASE2'],['PHASE2'],True,1.0,exact,Phase,protocolSection.designModule.phases,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.allocation,TP,TP,RANDOMIZED,RANDOMIZED,True,1.0,exact,DesignAllocation,protocolSection.designModule.designInfo.allocation,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.interventionModel,TP,TP,PARALLEL,PARALLEL,True,1.0,exact,DesignInterventionModel,protocolSection.designModule.designInfo.interventionModel,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.interventionModelDescription,EV,EV,,"Two principal study arms: (1) 5 mg placebo + 10 mg escitalopram and (2) 5 mg methylphenidate + 10 mg escitalopram, with option to escalate escitalopram dose to 20 mg at week 4 based on clinical improvement.",,,,DesignInterventionModelDescription,protocolSection.designModule.designInfo.interventionModelDescription,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.maskingInfo.masking,TP,TP,QUADRUPLE,QUADRUPLE,True,1.0,exact,DesignMasking,protocolSection.designModule.designInfo.maskingInfo.masking,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.maskingInfo.maskingDescription,EV,EV,,"Study medications were formulated into identical compound capsules. Bottles were labeled with 'Study Drug A', 'Study Drug B', 'Study Drug C' or 'Study Drug D'. The randomization sheet was provided by the primary statistician who was not involved in clinical assessments and given directly to the pharmacist. Investigators and participants were kept blinded during the study window until data collection and analysis were completed. All study physicians, nurses and research assistants who worked directly with participants were blinded to treatment allocation. Only the study statistician and one additional staff member assigned to work with the compounding pharmacy were unblinded.",,,,DesignMaskingDescription,protocolSection.designModule.designInfo.maskingInfo.maskingDescription,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.maskingInfo.whoMasked,TP,TP,"['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']","['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']",True,1.0,exact,DesignWhoMasked,protocolSection.designModule.designInfo.maskingInfo.whoMasked,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.enrollmentInfo.count,TP,TP,23,20,True,0.9,success,EnrollmentCount,protocolSection.designModule.enrollmentInfo.count,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[2].type,EV,EV,,DEVICE,,,,InterventionType,protocolSection.armsInterventionsModule.interventions.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[2].name,EV,EV,,Medication Electronic Monitoring System (MEMS),,,,InterventionName,protocolSection.armsInterventionsModule.interventions.name,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[2].description,EV,EV,,Study medication bottles were equipped with MEMS caps to track adherence by recording the date and time of each bottle opening. This was used as the secondary endpoint for measuring adherence.,,,,InterventionDescription,protocolSection.armsInterventionsModule.interventions.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[2].armGroupLabels,EV,EV,,"['Placebo + Escitalopram', 'Methylphenidate + Escitalopram']",,,,InterventionArmGroupLabel,protocolSection.armsInterventionsModule.interventions.armGroupLabels,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[0].measure,EV,EV,,Beliefs About Medicines Questionnaire (BMQ) Score,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[1].measure,EV,EV,,Remission Rate,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[2].measure,EV,EV,,Response Rate,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[3].measure,EV,EV,,Change in QIDS-SR Score,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[0].description,EV,EV,,Categorization of participants into accepting/ambivalent vs. indifferent/skeptical groups based on their attitudes toward medication,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[1].description,EV,EV,,Defined by a score of ≤5 on the Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR),,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[2].description,EV,EV,,Defined by a 50% reduction in symptoms on the QIDS-SR,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[3].description,EV,EV,,Change from baseline (Week 0) in QIDS-SR score measuring depressive symptom severity,,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[0].timeFrame,EV,EV,,"Weeks 0, 2, 4, and 8",,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[1].timeFrame,EV,EV,,Week 8,,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[2].timeFrame,EV,EV,,Week 8,,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[3].timeFrame,EV,EV,,"Weeks 0, 1, 2, 3, 4, 6, and 8",,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.eligibilityCriteria,TP,TP,"Inclusion Criteria:

* Baseline QIDS-SR ≥ 14 (moderate depression)
* Age 18 - 65
* Written Informed Consent
* Major Depressive Disorder, single-episode/recurrent, not in remission

Exclusion Criteria:

* RT2CK17-related exclusions
* Uncontrolled hyperthyroidism
* Glaucoma
* Motor tics
* Monoamine oxidase inhibitor treatment
* Serious coronary artery disease, cardiomyopathy, serious cardiac arrhythmias
* Uncontrolled hypertension
* Peripheral vasculopathy
* Pregnancy
* Bipolar Disorder
* Psychotic Disorder
* History of intolerability of study medications
* Currently taking psychiatric medications
* Current Substance Use Disorder (other than nicotine)
* Current Alcohol Use Disorder","Inclusion Criteria:
- Baseline QIDS-SR ≥ 14 (moderate depression)
- Age 18–65 years
- Ability to give written informed consent
- MDD single-episode/recurrent, not in remission

Exclusion Criteria:
- MPH-related exclusions (i.e. uncontrolled hyperthyroidism, glaucoma, motor tics, monoamine oxidase inhibitor treatment, serious coronary artery disease, cardiomyopathy, serious cardiac arrhythmias, uncontrolled hypertension, peripheral vasculopathy, pregnancy)
- Diagnosis with the following mental health conditions: bipolar disorder, psychotic disorder, current substance use disorder (other than nicotine), current alcohol use disorder
- History of intolerability of study medications
- Currently taking psychiatric medications",True,0.99,success,EligibilityCriteria,protocolSection.eligibilityModule.eligibilityCriteria,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.healthyVolunteers,TP,TP,False,False,True,1.0,exact,HealthyVolunteers,protocolSection.eligibilityModule.healthyVolunteers,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.sex,TP,TP,ALL,ALL,True,1.0,exact,Sex,protocolSection.eligibilityModule.sex,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.minimumAge,TP,TP,18 Years,18 Years,True,1.0,exact,MinimumAge,protocolSection.eligibilityModule.minimumAge,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.maximumAge,TP,TP,65 Years,65 Years,True,1.0,exact,MaximumAge,protocolSection.eligibilityModule.maximumAge,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.stdAges,TP,TP,"['ADULT', 'OLDER_ADULT']","['ADULT', 'OLDER_ADULT']",True,1.0,exact,StdAge,protocolSection.eligibilityModule.stdAges,False,True,True,False,True,False
